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Fetal scalp sampling in labour
Lactate measurement has benefits over pH estimation
In the linked randomised controlled trial, Wiberg-Itzel 
and colleagues compare the effectiveness of two meth-
ods of diagnosing hypoxia in the fetus during labour—
scalp pH analysis and scalp lactate analysis.1 
Fetal wellbeing during labour depends on several 
factors—an adequate supply of oxygenated maternal 
blood reaching the placental intervillous space, gas 
exchange across an undamaged placenta, supply of 
oxygenated blood to the fetus through an open umbili-
cal vein, and sufficient metabolic reserve in the fetus 
to withstand the hypoxic effects of uterine contrac-
tions. The fetus may be compromised by maternal 
hypotension, prolonged uterine contractions, placental 
abruption, umbilical cord occlusion, and fetal growth 
restriction. Distress may also occur for no obvious 
reason in apparently normal labours.
The traditional mainstay of fetal assessment during 
labour is monitoring of the fetal heart rate—either by 
intermittent auscultation (using a Pinard stethoscope or 
hand held Doppler device) or by continuous electronic 
monitoring. Compared with intermittent auscultation, 
continuous electronic monitoring has the disadvantage 
that it restricts the woman’s movement. It also increases 
the need for caesarean section (relative risk 1.66, 95% 
confidence interval 1.30 to 2.13) and instrumental  vaginal 
delivery (1.16, 1.01 to 1.32), but is less likely to result in 
the neonate having seizures because of hypoxic brain 
insults (0.50, 0.31 to 0.80).2 A trade-off therefore exists 
between the benefits and harms of the two methods. If 
628 women had continuous electronic monitoring there 
would be one less neonatal seizure and 11 more caesar-
ean sections compared with intermittent auscultation.2
Both approaches to monitoring fetal heart rate lack 
specificity. Intermittent slowing of the heart rate does not 
necessarily indicate serious compromise. In particular, 
“variable decelerations”—caused by cord compression—
may be associated with marked and audible drops in the 
fetal heart rate but are often benign. Adjunctive methods 
of fetal assessment are therefore needed in the presence 
of worrying features that are not severe enough to war-
rant immediate delivery. Fetal scalp sampling to measure 
capillary blood pH has provided that function for dec-
ades.3 The baby’s scalp is visualised through a tapered 
cylindrical amnioscope that is inserted into the vagina, 
and capillary blood is obtained via a stab wound.
However, the procedure is awkward, intrusive, 
and uncomfortable. A recent study found that it takes 
longer to perform than most obstetricians realise. 
Of 100 consecutive attempts at scalp sampling, 11 
failed completely. The mean time between making 
the decision to sample and obtaining a pH result was 
18 minutes. The median time to take a sample after 
preparations were made and the woman positioned 
was 14 minutes. The median time to abandoning the 
procedure in cases of failure was 26 minutes.4
The value of estimating capillary blood pH is also 
uncertain. A recent review on fetal heart monitor-
ing found no evidence that access to scalp sampling 
reduced the risk of neonatal seizures or of caesarean 
section.2 The intrapartum care guideline issued by the 
National Institute for Health and Clinical Excellence in 
2007 acknowledged the lack of a satisfactory evidence 
base, but it concluded that clinical experience and 
indirect research comparisons justified a recommen-
dation that fetal scalp sampling should be used when 
the fetal heart trace was pathological.5 Consequently, 
and because this is a procedure that features promi-
nently in an expensive medicolegal arena, anything 
that improves the ease of scalp sampling or provides a 
less invasive alternative is welcome. 
Wiberg-Itzel and colleagues report a multicentre 
Swedish randomised controlled trial of almost 3000 
women, which compared scalp pH analysis with scalp 
lactate analysis.1 Lactate concentrations reflect tissue 
hypoxia and consequent anaerobic metabolism. Meas-
urement of fetal capillary lactate concentrations during 
labour was described in the early 1980s,6 but the tech-
nique failed to catch on in clinical practice. With tech-
nological advances, lactate can be reliably measured 
using small amounts of fetal blood (5 μl).7 In contrast, 
pH analysis requires 30-50 μl of blood.
Wiberg-Itzel and colleagues found no significant dif-
ference between rates of metabolic acidaemia at birth 
after use of lactate analysis or pH analysis of fetal scalp 
blood samples to determine hypoxia during labour 
(0.91, 0.61 to 1.36 v 0.84, 0.47 to 1.50). However, sig-
nificantly more protocol violations occurred for pH 
estimation (10.4%) than for lactate estimation (1.2%), 
mainly because of failed sampling. The authors did not 
record the time taken to perform sampling, but it was 
thought to be shorter for lactate estimation because of 
the smaller samples needed. Economic data were not 
reported. This study, together with a smaller earlier 
trial,8 supports the use of lactate measurement rather 
than pH estimation at fetal scalp sampling.
Do less invasive alternatives exist? The most promis-
ing is analysis of the ST segment of the electrocardio-
graphic signal obtained from an electrode attached to 
the fetal scalp. The adjunctive use of ST segment analy-
sis along with cardiotocography decreases the need for 
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assessing patients’ improvement in clinical trials
should the doctor or patient judge improvement, and does it matter?
scalp sampling and instrumental vaginal deliveries com-
pared with cardiotocography alone.9 The logical next 
step is a head to head comparison of the two adjunctive 
methods—fetal scalp sampling versus ST segment analy-
sis. This trial is ongoing in the Netherlands.10 
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Doctors need to understand the benefits of new treat-
ments from patients’ perspectives, because they must 
judge the relative risks and benefits of offering such 
treatments to patients. The field of health status assess-
ment has evolved to meet this need, and several patient 
completed instruments have been developed that are 
valid, reliable, and sensitive to treatment.1 Such tools 
can provide invaluable insights into how a treatment 
affects outcomes such as function and quality of life, 
which can be more important to patients than sur-
vival.2-4 For some conditions, however, measures of 
disease specific health status are not available, and 
global assessments of clinical change are used.
Although valid approaches are available for measur-
ing global change experienced by patients,5 6 simple 
ad hoc measures are often used and can be assessed 
from the perspective of the patient or the doctor. In the 
linked survey of trials included in systematic reviews, 
Evangelou and colleagues determine whether patients 
and doctors differ in their assessments of global change 
after experimental treatments.7
Given the reliance of studies on global assessments 
of clinical change and the convenience of the doctor 
doing the assessment, the correlation between patients’ 
 assessments and doctors’ assessments is important. The 
studies included in Evangelou and colleagues’ review 
were mostly from the fields of rheumatology and 
 psychiatry. The authors found a close correlation between 
the two assessments, which suggests that either should 
suffice when measuring the benefits of treatment from the 
patient’s perspective. However, although they performed 
a thorough and methodologically sound literature review, 
their  findings may provide false reassurance.
In the field of cardiology, doctors’ assessments 
have been shown to be biased and unreproducible. 
The New York Heart Association (NYHA) classifica-
tion of functional status in heart failure is meant to 
measure patients’ symptoms and functional limitations 
on a four point scale. But interobserver variability is 
high—agreement between independent assessors is only 
55%.8 9 Similarly, clinical investigators’ and objective 
interviewers’ assessments of the severity of angina have 
been shown to be biased.10 If reproducible assessments 
cannot be determined at a single point in time, it is 
unlikely that doctors will be able accurately to represent 
changes over time. Yet, as Evangelou and colleagues 
note, such formal investigation of doctors’ ability to 
measure change has rarely been performed.
Rather than rely on such crude assessments, clinicians 
need clinical trials to investigate patients’ perspectives of 
their disease through the serial assessment of valid, relia-
ble, and responsive disease specific health status question-
naires.11 For example, the Kansas City cardiomyopathy 
questionnaire, a disease specific measure for patients with 
heart failure, is more sensitive to clinical change than the 
NYHA,six minute walk test and several generic instru-
ments.12 Moreover, such measures can identify which 
domains (for example, symptoms, physical function 
or social function, etc) are most affected by treatment. 
This information allows patients to have a more realistic 
expectation of the benefits from a proposed treatment. 
When disease specific measures do not exist, generic 
measures of health status should be considered. Only 
through the use of psychometrically sound measures can 
clinicians obtain an accurate assessment of how a treat-
ment affects a patient’s disease process and effectively 
communicate that information to the patient.
Several possible explanations exist for the discrep-
ancy between Evangelou and colleagues’ findings and 
the well documented limitations of doctors’ assessments 
of patients’ health status. Firstly, because the authors used 
summary data from reviews rather than raw data from 
clinical observations, they had to rely on group means 
and may not have appreciated the individual variability 
of each doctor’s assessment. Secondly, the clinical mani-
festations of the diseases studied may correlate better 
with patient’s quality of life than other conditions such as 
cardiovascular disease. Thirdly, the different measure-
ments of clinical change used in the studies included in 
the reviews may minimise important differences in per-
spectives of clinical change that would have been more 
evident with better assessment measures.5 6
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Interestingly, failure to control for variability in the 
duration of the studies and the potential for recall bias 
regarding patients’ original health status is more likely 
to have introduced biases that produce greater dif-
ferences between patients’ assessments and doctors’ 
assessments. Finally, because patients are often at a 
nadir in their disease when enrolled in a clinical trial, 
a background trend for improvement may have artifi-
cially accentuated the similarities between the patients’ 
assessments and the doctors’ assessments.
Researchers should be encouraged to study the cor-
relations between alternative methods of assessing 
patients’ clinical status in other diseases and clinical 
settings. More importantly, however, serial changes 
in patients’ health status, as assessed by patients them-
selves, should increasingly be used to document the 
benefits of treatment. This would obviate the need to 
rely on global assessments from either the patients’ 
perspective or the doctors’ perspective.
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Patient consent—decision or assumption?
New guidance from the general medical Council urges a change in approach
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The process of obtaining consent from patients for pro-
cedures such as surgical operations has been described 
as “the modern clinical ritual of trust,”1 although its real 
meaning and performance are still debatable.2 Last week, 
the General Medical Council released new guidance on 
the subject, Consent: Patients and Doctors Making Decisions 
Together, that will be implemented in June 2008.3 
To caricature, obtaining consent often involves a junior 
member of the clinical team being charged with obtain-
ing a signed piece of paper declaring that the patient has 
understood the nature of the procedure and its conse-
quences. Consent is often completed a few hours before 
the intended procedure, and patients seldom have time 
to read, never mind reflect on, information about pos-
sible harms and benefits—rare or otherwise.
Although the consent discourse has hardly been stud-
ied in depth, many clinicians report the process of obtain-
ing consent from patients as a perfunctory chore—to be 
accomplished in a superficial albeit efficient way—to 
ensure a smooth transition from preoperative assess-
ment to preparation for the operating theatre. In the real 
world of rapid throughputs and turnaround times, con-
sent is—and often has to be—assumed. Evidence shows 
that patients want to be given more relevant information 
about risks and consequences.4 This emphasises the fun-
damental aim of informed consent—that patients should 
be neither coerced nor deceived.2
The new GMC guidance urges doctors to re-think 
their approach.3 It advocates the communication of risks; 
it advises what should be done when patients refuse treat-
ment; and it notes changes in the law, including the new 
legal safeguards for patients who lack capacity to make 
their own decisions. It encourages doctors and patients 
to be actively engaged in discussions about investigations 
and treatment, to enable patients to make informed deci-
sions that are tailored to their individual circumstances 
and beliefs. The guidance stresses that obtaining and 
giving consent should not be a “tick the box” exercise 
but should be based around nine fundamental points 
(see box on bmj.com).3
So what are the implications for what clinicians do 
in practice? At first reading, the guidance seems radical 
and seems to signal a cultural change in how informed 
consent should be achieved. Yet closer reading reveals 
broad brushstrokes—details are sparse and the advice 
remains non-specific. For example, the guidance pro-
vides no detail about suggested risk thresholds for speci-
fying the probability of harm; in addition, it makes no 
suggestions on how to achieve balance, how to tailor 
information, or how to explore personal preferences.
Considerable progress has been achieved in many of 
these areas in the related fields of risk communication, 
shared decision making, and decision support.5 Guidance 
on how to communicate risk—using graphics, negative 
framing, and positive framing; describing both absolute 
(baseline) and relative risk estimates; and deploying 
natural frequencies rather than percentages—have been 
published.6 Although the GMC’s guidance looks like a 
manifesto for shared decision making,7 it stops short of 
describing how clinicians could achieve these challenges 
1260   BMJ | 7 June 2008 | VoluMe 336
eDITORIaLs
in busy clinical settings.8 The lack of detail might pre-
vent many clinicians from making major changes to their 
practice, perhaps just introducing patient information 
material, which may be of dubious quality.9 Neverthe-
less, the arrival of new guidance signals the need for an 
overhaul of how informed consent needs to be achieved 
for clinicians who are keen to make improvements.
What needs to happen before the guidance can be 
implemented? Systemic and cultural change is needed 
to move shared decision making beyond interactions 
between health professionals and patients into the realm 
of becoming a requirement at the organisational level, 
integrated into the way multidisciplinary teams are set 
up to provide care. Rather than remain a bureaucratic 
task, consent would become a step-wise conversation 
conducted over numerous contacts.10 Information 
would be provided early, preferably as soon as inter-
vention is a possibility. The task of obtaining consent 
would be a distributed responsibility, conducted and 
documented by a series of clinicians working to a com-
mon goal. The process would become a consent path-
way, with clear steps where information and patient 
preference would be considered and documented.
A signature on a consent form would no longer be suf-
ficient evidence that the patient had been given  accurate 
and tailored information. New materials will be needed 
that contain data about the intervention being considered, 
the likely outcomes, and their  probabilities, complete 
with guidance on how to clarify patients’ preferences 
and deliberate about options. Generating these materials 
will require considerable investment and expertise, both 
in the synthesis of evidence and in the presentation of 
the information. There is, however, much experience in 
producing such tools—decision support technologies, also 
The carers of people with dementia
Want high quality services and have compelling reasons to get them
ReseaRch, p 1295 
Rob Butler consultant 
psychiatrist, Older Peoples’ 
mental Health service, Redwald 
Unit, st Clement’s Hospital, 
ipswich, suffolk iP3 8Ls 
Robbutler100@hotmail.com
Competing interests: None 
declared.
Provenance and peer review: 
Commissioned; not externally 
peer reviewed. 
BMJ 2008;336:1260-61
doi: 10.1136/bmj.39567.647072.80
Carers of people with dementia have a hard time; not 
only do they have to contend with the illness but they 
also receive limited support and poor services. A recent 
UK parliamentary committee report criticised the whole 
range of dementia care.1 It highlighted poor diagnosis 
(only a third of people with dementia receive a formal 
diagnosis), fragmented home support, untrained staff in 
care homes, and a failure to recognise or manage demen-
tia in general hospitals. This leaves difficult decisions for 
those redesigning services. Who will offer long term sup-
port? What will be the role of the voluntary sector? In 
the accompanying paper, Charlesworth and colleagues 
tackle these questions in a randomised controlled trial of a 
scheme for befriending carers of people with dementia.2
Carers have high rates of anxiety, stress, and burnout. 
Their life expectancy is reduced, and up to a third of car-
ers of people with dementia are depressed.3 4 During the 
course of dementia, the stresses for carers change. Across 
Europe, fewer than a quarter of carers say that services 
are sufficient to meet their needs.5
Care of dementia in the United Kingdom costs more 
than £17bn (€22bn; $34bn) a year. Breakdown in sup-
port from carers is a major cause of people moving into 
care homes, and accommodation accounts for more 
than 40% of the total financial cost of dementia.6 Carers 
already save UK tax payers £6bn a year so they are vital 
for keeping down spiralling costs. Carers face consider-
able financial costs themselves because many have to 
give up work or reduce their hours.6 By supporting car-
ers we may be able to help people with dementia to stay 
living at home for longer and free up money to spend on 
other parts of the service.
So how can we support carers? A range of support 
has been evaluated, including telephone information, 
education, mutual support, cognitive behavioural ther-
apy, problem solving, and case management.7 One 
randomised controlled trial in carers of people with 
dementia found that six counselling sessions, group 
support, and the availability of telephone counselling 
reduced the rate of placement in a nursing home by 
known as decision aids, are on the increase.11
The international patient decision aids standards col-
laboration is working to ensure that quality assurance 
criteria exist.12 These tools did not originate as methods 
to ensure informed consent—they were devised to help 
patients consider tough decisions, where clinical equi-
poise exists. However, as consent becomes increasingly 
regarded as a form of choice that involves a deliber-
ated decision rather than just acceptance of professional 
advice, the shift to adopt decision support technologies 
as a means of achieving informed consent seems not 
only necessary, but inevitable.
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28%.8 However, overall, interventions aimed at sup-
porting or providing information to carers of people 
with dementia have produced disappointing results, 
and high quality trials are sparse. Research into 
dementia is under-represented and accounts for only 
a 20th of the number of research papers on cancer.6
Charlesworth and colleagues tested access to befriend-
ing schemes as support for family carers of people with 
dementia.2 The befriending schemes were run by local 
voluntary bodies. The study found no significant differ-
ence in mood or quality of life at 15 months’ follow-up 
between carers who had access to a befriender compared 
with those who did not. However, only half of those 
offered befriending used the service, and only a third 
completed six months of befriending. Those who used 
the service tended to have little existing contact with 
family or friends.
What are the implications of these results? At face value 
they might suggest that resources should not be used to 
fund access to befriending. However,  befriending is a per-
sonal activity that works well for some carers at certain 
times. The trial shows that this is important because most 
of the carers who completed six months of befriending 
were still in contact with the  befrienders one year after 
the start of the trial. Existing supports and the quality of 
services may influence the effects of befriending.
So, how can we provide carers with high quality 
 services? Several randomised controlled trials have 
shown better models of care. In the United States, 
providing a senior nurse to coordinate services—such 
as  treatment and education—in primary care reduced 
 distress in people with dementia and improved 
 depression in carers.9 Another trial in the US found that 
a disease management programme led by care managers 
improved quality of life for the person with dementia.10 
In the Netherlands, a detailed clinic based assessment by 
doctors, nurses, and other professionals which was sent 
to primary care also improved quality of life for people 
with dementia.11 The UK government has launched the 
first national dementia strategy, which should be pub-
lished at the end of this year.12 Its priorities are improved 
awareness, early diagnosis and intervention, and better 
quality of care for dementia.
The UK parliamentary committee made several rec-
ommendations to improve the care of dementia.1 One of 
these is to offer everyone with dementia and their carer 
a single health or social care professional contact point. 
Although this will require extra resources, the reasons to 
implement a fully funded strategy are compelling.
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Vertebroplasty for osteoporotic vertebral fracture
Consensus on the indications is needed to avoid indiscriminate use
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The first percutaneous injection of bone cement into 
the spine was performed in 1984 to treat a 54 year old 
woman with extreme pain caused by a haemangioma 
in the second cervical vertebra. Surprisingly, pain relief 
was complete.1 After the case was published, indica-
tions for percutaneous vertebroplasty quickly expanded 
to include treatment of chronic back pain caused by 
metastases and osteoporotic fracture.
Since then, many case series have indicated that 
vertebroplasty is an effective way to control the 
pain of vertebral compression fracture caused by 
osteoporosis. The immediate relief of pain is often 
dramatic and, especially for the chronically debili-
tated patient, it may seem miraculous. The results 
are fairly consistent, and in one large case series of 
552 patients, improvement in pain and  disability 
persisted throughout two years of follow-up.2 
 Unfortunately, in the only published randomised 
controlled trial of vertebroplasty, almost all patients 
in the control group—who received conservative 
care—crossed over to the intervention group two 
weeks after randomisation, so the results were dif-
ficult to interpret.3 
At present, guidelines for selecting which patients 
to treat with vertebroplasty are vague. The National 
Institute for Health and Clinical Excellence (NICE) 
interventional procedure guidance 12 states that “the 
procedure should be limited to patients whose pain 
is refractory to more conservative treatment.” With 
respect to efficacy, “the opinions of the specialist advi-
sors were divided.”
Standards of care for debilitated patients 
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vary greatly between jurisdictions as a result of 
 differences in home support, insurance coverage, or 
access to private care. Rigorous supervision of non-
hospital care before vertebroplasty may be difficult 
for the specialist physician trying to ensure that all 
patients undergo “adequate trial of optimised con-
servative treatment.” The problem is exaggerated 
if patients have difficulty in travelling to and from 
appointments—in Canada and the United States 
home visits by doctors are rare.
In some centres in North America, patients with 
“failure of conservative treatment” can be directly 
referred for vertebroplasty by emergency depart-
ments. In this setting, the effects of the procedure 
may be exaggerated for several reasons—patients 
are very appreciative of rapid pain relief; doctors’ 
perceptions of results are positively reinforced by 
the immediacy of the effect and early discharge 
from hospital; and the hospital administration may 
benefit financially. The problem is compounded 
in health systems that reward action rather than 
observation and in clinical services that compete 
to provide “better care.” In this context, failure of 
conservative treatment could become a euphemism 
for inadequate care.
So what constitutes failure of conservative man-
agement? No definition of a standard approach 
for initial conservative treatment can be found in 
the literature. No agreed guidelines exist for the 
minimum duration of conservative management or 
whether this should vary according to age or con-
dition. Options for conservative care are seldom 
described in any meaningful way. For example, high 
dose calcitonin for controlling pain of bony origin is 
rarely considered, even though it is a highly effec-
tive analgesic for osteoporotic vertebral fracture.4 5 
Only occasionally is advice given about bed rest.6 
Furthermore, few publications stress the palliative 
nature of vertebroplasty, especially in osteoporo-
sis, and that the procedure does have risks. Serious 
complications of vertebroplasty include paraplegia, 
pulmonary cement embolism, and death.7
A recently published position statement on 
 percutaneous vertebral augmentation with verte-
broplasty or kyphoplasty (balloon vertebroplasty) 
discussed the evidence for the poor prognosis of 
chronic pain and disability in elderly people. This 
evidence is used as a justification for vertebroplasty, 
and the statement concludes that this procedure is 
“established therapy and should be reimbursed by 
payors as a safe and effective treatment for painful 
compression fractures.”8 However, although early 
follow-up results of two non-randomised controlled 
studies showed significant improvement in pain in 
the vertebroplasty group, three or six months later 
the differences between groups were not sustained.9 
10 There is no good evidence that vertebroplasty has 
a better long term outcome, and it may even accel-
erate the rate of new fractures.11 12 Also, because 
vertebroplasty does not treat the underlying condi-
tion, if immediate pain relief detracts attention away 
from the seriousness of the osteoporosis, might this 
constitute an adverse effect?
Although evidence is currently lacking, immedi-
ate access to vertebroplasty could be more effec-
tive than conservative treatment. Conservative 
measures such as narcotic analgesia and bed rest 
have side effects that are often magnified in elderly 
debilitated people. Hospital care is expensive and 
faster rehabilitation may be preferable. However, 
without high quality evidence, selection criteria for 
the procedure may become less clear over time 
as new devices and instruments are developed to 
expand the application of the technique. Competi-
tion between manufacturers is more likely to cloud 
rather than to clarify these matters.
With good training and equipment, vertebroplasty 
is a relatively simple interventional procedure; its 
immediate effects are well documented; and its use 
is perhaps justified as a treatment for severe chronic 
debilitating pain caused by osteoporotic vertebral 
fracture. Of course these decisions should be made 
by a multidisciplinary team of clinicians experi-
enced in osteoporosis, pain and rehabilitation, and 
vertebroplasty, who would be responsible for man-
agement and follow-up. Randomised controlled tri-
als are essential to define the minimum conservative 
treatment that patients should receive before ver-
tebroplasty, and to develop clear guidelines on the 
use of vertebroplasty that would help to prevent its 
indiscriminate use.
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